Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 19095497

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2009 Jan
First author
Cheng AL

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2009 Jan;10(1):4-5. doi: 10.1016/S1470-2045(08)70317-6.
    note
    Source null
    related pmid
    19111238
    relationship
    Comment in
  2. citation
    Gastroenterology. 2009 Sep;137(3):1171-3. doi: 10.1053/j.gastro.2009.07.008.
    note
    Source null
    related pmid
    19632249
    relationship
    Comment in

Authors and identifiers

  1. name
    Cheng AL
    type
    Author
  2. name
    Kang YK
    type
    Author
  3. name
    Chen Z
    type
    Author
  4. name
    Tsao CJ
    type
    Author
  5. name
    Qin S
    type
    Author
  6. name
    Kim JS
    type
    Author
  7. name
    Luo R
    type
    Author
  8. name
    Feng J
    type
    Author
  9. name
    Ye S
    type
    Author
  10. name
    Yang TS
    type
    Author
  11. name
    Xu J
    type
    Author
  12. name
    Sun Y
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Cheng AL
    type
    Author
  2. name
    Kang YK
    type
    Author
  3. name
    Chen Z
    type
    Author
  4. name
    Tsao CJ
    type
    Author
  5. name
    Qin S
    type
    Author
  6. name
    Kim JS
    type
    Author
  7. name
    Luo R
    type
    Author
  8. name
    Feng J
    type
    Author
  9. name
    Ye S
    type
    Author
  10. name
    Yang TS
    type
    Author
  11. name
    Xu J
    type
    Author
  12. name
    Sun Y
    type
    Author
bibliography ids
  1. nci-bib-0047c55b159e72041d48b177
book metadata
content sha256
bd861374d55ae2829d2d509e7b66431d8c6a2f574e126cdcaa45743c76f7caf1
document type
citation
dois
  1. 10.1016/S1470-2045(08)70285-7
electronic publication date
display
2008 Dec 16
precision
day
year
2008
evidence scope
bibliographic_metadata_only
id
pubmed:19095497
immutable id
pubmed:19095497@bd861374d55ae2829d2d509e7b66431d8c6a2f574e126cdcaa45743c76f7caf1
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
25-34
volume
10
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2009 Jan;10(1):4-5. doi: 10.1016/S1470-2045(08)70317-6.
    note
    Source null
    related pmid
    19111238
    relationship
    Comment in
  2. citation
    Gastroenterology. 2009 Sep;137(3):1171-3. doi: 10.1053/j.gastro.2009.07.008.
    note
    Source null
    related pmid
    19632249
    relationship
    Comment in
outcomes validated
false
pmid
19095497
provenance
batch id
27a383f06e5fc3d04fad
provider
NCBI PubMed ESummary
record sha256
c2f3719607c81953fb6a5a5b543a2b572d054d37192e5be24f35beae4c50ee7f
response sha256
51f0f2a142dbd9b135e872b049b116f51941299445a5416feae10f12fac8d978
retrieved at
2026-09-09T23:46:24.265787+00:00
publication date
display
2009 Jan
precision
month
year
2009
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/19095497/
title
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Preserved source evidence · Not medical advice